CNS Pharmaceuticals Inc (CNSP)

Form 8-K - Current report

CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment

Access the segment here HOUSTON, TX / ACCESS Newswire / June 8, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the...

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 4 - Statement of changes in beneficial ownership of securities

Form D - Notice of Exempt Offering of Securities

Form S-3 - Registration statement under Securities Act of 1933

CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress

Oversubscribed $22.5 million financing anticipated to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing

The private placement includes participation from several leading healthcare investors including ADAR1 Capital, Ikarian Capital, Stonepine Capital...

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report